Stockholders Equity |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Stockholders Equity | |
| Stockholders' Equity | Note 6. Stockholders’ Equity
At June 30, 2026 and December 31, 2025, the Company had 37,404,544 and 33,407,495 common shares outstanding, respectively (including outstanding restricted stock awards (RSAs) and performance-based restricted stock awards (PSAs) totaling 2,221,169 shares and 2,090,946 shares, respectively). No preferred shares were outstanding at June 30, 2026 and December 31, 2025.
At-the-Market (ATM) Offerings
The Company has entered into sales agreements with agents pursuant to which the Company may issue and sell shares of its common stock in “at-the-market” (ATM) equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The Company records its ATM sales on a settlement date basis. The sales commissions and expenses related to each ATM program are considered direct and incremental costs and are charged against “Additional paid-in capital” on the consolidated balance sheets in the period in which the corresponding shares are issued and sold.
During the three months ended June 30, 2026, the Company sold an aggregate of 2,392,247 shares under its sales agreement with Jefferies, LLC (Jefferies), resulting in aggregate net proceeds of $25.8 million. During the three months ended June 30, 2025, the Company sold an aggregate of 3,636,647 shares under its sales agreement with Jefferies and under a previous sales agreement with Stifel, Nicolaus & Company (Stifel), resulting in aggregate net proceeds of $42.9 million.
During the six months ended June 30, 2026, the Company sold an aggregate of 3,752,460 shares under its sales agreement with Jefferies, resulting in aggregate net proceeds of $44.4 million. During the six months ended June 30, 2025, the Company sold an aggregate of 6,242,266 shares under its sales agreement with Jefferies and under a previous sales agreement with Stifel, resulting in aggregate net proceeds of $63.1 million.
The Company has a $350 million shelf registration statement on Form S-3 (File No. 333-291837). As of June 30, 2026, approximately $96.1 million of our common stock remained available for issuance and sale under the Company’s $150 million at-the-market offering program pursuant to the related prospectus supplement, as amended. |